Glioblastoma (GBM) 🌟, an aggressive and fast-growing brain cancer 🧠, became smaller after dual-target CAR T-cell therapy 💉 in nearly two-thirds of patients. Several patients lived 12 months or longer 🗓️ after receiving the therapy, which is notable given the typical survival is less than a year.
Read Full Article
#Glioblastoma #CARTcelltherapy #BrainCancer #CancerResearch #PatientHope
Read Full Article
#Glioblastoma #CARTcelltherapy #BrainCancer #CancerResearch #PatientHope
Penn Today
Dual-target CAR T-cell therapy slows growth of aggressive brain cancer | Penn Today
Researchers from Penn Medicine have demonstrated encouraging tumor reductions rarely seen in recurrent glioblastoma following phase I clinical trials.
🙏1